Skip to content
Information only — we do not sell or supply products, and nothing here is professional advice.
Peptide Help USA

Guides

Peptide Therapy Guides

Last updated 2026-06-15 · Reviewed for accuracy by Editorial Team

Plain-English, educational guides to how peptide therapy actually works in the US — how dosing is decided, what side effects to watch for, how injections are handled, and how to choose a legitimate provider. No protocols, no sourcing — just the context you need before you talk to a clinician.

This is the practical side of peptide therapy — the “how does this actually work, and what should I know before I commit” material. The Reference library explains what each compound is and what the evidence says; these guides focus on using a therapy responsibly: how dosing is decided, what side effects get reported, how injections are handled, and how to tell a legitimate provider from a gray-market one.

A note on what you won’t find here. We don’t publish injection recipes or “start at X, increase by Y” ladders. For most of these compounds that isn’t a cautious editorial choice — it’s a safety one. With the exception of approved drugs like the GLP-1 medicines and tesamorelin, these peptides aren’t FDA-approved, and much of what’s sold online is research-grade material of unknown concentration and purity. A “standard internet dose” applied to an unverified vial is still unsafe. So we treat dosing as a topic — how a prescriber decides it, what changes it, why fixed online numbers are risky — rather than a protocol to copy.

The US regulatory picture is also moving fast. In April 2026 the FDA removed a group of widely discussed peptides (including BPC-157, TB-500, and MOTS-c) from its Category 2 compounding-restriction list, and a Pharmacy Compounding Advisory Committee review is scheduled for late July 2026 to consider returning several to the Category 1 503A bulks list. None of that is the same as FDA approval, and formal rulemaking is still pending. Where a guide touches legality, it’s current as of its update date and may change — always cross-check the Access & Legality section.

Start with the fundamentals

If you’re new to peptides, read these four first. They give you the framework the compound-specific guides build on.

Guides by compound

Each compound below has a dosing guide (how it’s used and how that’s decided) and a side-effects guide (what’s reported and what to watch for).

Metabolic & weight-loss peptides

Healing & tissue-repair peptides

Growth-hormone secretagogues

Recovery, immune & cellular peptides

Cosmetic, sexual & nootropic peptides

Note: A guide existing here is not an endorsement that a compound is safe, effective, or legal to obtain. Several of these — Melanotan-2 in particular — carry genuine safety concerns and have no approved US pathway. Each individual guide is honest about where the evidence and the law actually stand.

Where to go next

Once you understand how dosing and providers work, the Access & Legality guides cover the legitimate routes — telehealth, 503A compounding with a prescription, in-person clinics — and the current status of the 2026 FDA reclassification. For the science behind each compound, start in the Reference library.

Frequently asked questions

What do these peptide guides cover?

They explain the practical side of peptide therapy: how dosing is decided and individualized, what side effects are reported, how injections are handled by clinicians, and how to evaluate a clinic or telehealth provider. Each compound also has its own dosing and side-effects guide.

Do these guides give dosing protocols I can follow?

No. We treat dosing as a topic, not a recipe. Peptide doses are set by a licensed prescriber for a specific person based on goals, labs, and response — a fixed number copied from a website, applied to an unverified gray-market product, is unsafe. The guides explain how dosing is decided, not what to inject.

Are the peptides in these guides legal in the US in 2026?

It varies. GLP-1 medicines like semaglutide and tirzepatide are FDA-approved drugs. Most others (BPC-157, TB-500, CJC-1295, and similar) are not approved; in April 2026 the FDA removed several from its Category 2 compounding-restriction list, and a Pharmacy Compounding Advisory Committee review is scheduled for July 2026, but formal reinstatement to Category 1 is still pending. See our Access & Legality guides for current detail.

Ask a question

Get guidance for your situation

Send your question and we'll point you to the right information. General information only — never sales pressure.

  • General information only — never sales pressure.
  • Your details are used to reply to you, nothing else.
  • We usually respond within 1–2 business days.